CX3CL1 and neoplasm: Interestingly, the highest CX3CL1 expression levels were found in grades III–IV tumors: oligodendrogliomas, anaplastic astrocytomas and glioblastomas, and correlated inversely with patient overall survival, but the receptor was present in similar levels, independent of tumor grade [218].